Clinical Trial Update: AC220 for Children With Relapsed/Refractory ALL or AML [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for AC220 in children with relapsed/refractory acute lymphoblastic leukemia or acute myeloid leukemia; study completed with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Lymphoblastic Leukemia Acute Childhood
• Myelogenous Leukemia Acute Childhood

Drugs mentioned

• AC220 (quizartinib)

Snippet

Sponsor: Therapeutic Advances in Childhood Leukemia Consortium | Conditions: Lymphoblastic Leukemia, Acute, Childhood, Myelogenous Leukemia, Acute, Childhood | Phase 1 | Status: COMPLETED | Results posted: 2020-02-20